Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer

OBJECTIVES:

• To assess the feasibility of radioimmunoguided intensity-modulated radiotherapy (IMRT) for stage I-IV prostate cancer.
• To determine the toxicity and tolerance of this regimen in these patients.
• To determine the tumor response based on physical examination and serial measurements of the serum prostate-specific antigen (PSA) levels in these patients.
• To determine the outcome of patients treated on this study with radioimmunoguided IMRT compared to 2 control groups of patients treated at Mayo Scottsdale Clinic (MSC).

OUTLINE: Patients undergo radioimmunoguided intensity-modulated radiotherapy once daily, 5 days a week for 8½ weeks. Beginning the last week of radiotherapy, some patients receive leuprolide acetate intramuscularly every 3-4 months or goserelin subcutaneously every 3 months for 6 months, 12 months, or until disease progression.

After completion of study treatment, patients are followed every 3-4 months for 1 year, every 6 months for 4 years and annually thereafter

DISEASE CHARACTERISTICS:

• Pathologically confirmed prostate cancer

• Stage I-IV disease (T1-4, N0-1, M0)
• No evidence of distant metastases (M0) on physical examination or bone scan

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Hemoglobin ≥ 10.0 g/dL
• WBC ≥ 3,000/mcL
• Platelet count ≥ 90,000/mm
• AST < 2 times the upper limit of normal
• No allergy to leuprolide acetate or goserelin

PRIOR CONCURRENT THERAPY:

• Not specified